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Abstract
Introduction: The aim of this study was to characterize anti-citrullinated peptide antibody (ACPA) serostatus in
pre-clinical rheumatoid arthritis (RA) with and without Human Leukocyte Antigen-Shared Epitope (HLA-SE) alleles.
Methods: We identified 192 women in the Nurses’ Health Study cohorts with blood samples obtained 4 months
to 17 years prior to medical record-confirmed RA diagnosis. Three controls were selected matched on age, cohort,
menopausal status and post-menopausal hormone use. Reactivities to 18 ACPAs were measured using a
custom BioPlex platform. We used conditional logistic regression to calculate the relative risk (RR) of RA for any
ACPA-positive and peptide-specific ACPA-positive and examined RRs by time between blood draw and RA onset.
Measures of multiplicative and additive interaction between any ACPA-positive and HLA-SE were calculated.
Results: All ACPAs by peptide groups were significantly associated with RA risk, RRs ranged from 4.7 to 11.7. The
association between ACPA and RA varied over time with the strongest association in those with blood draw less
t h a n5y e a r sb e f o r eo n s e t( R R1 7 . 0[ 9 5 %C I5 . 8t o5 3 . 7 ] )a n dn oa s s o c i a t i o n1 0o rm o r ey e a r sp r i o rt oo n s e t( R R1 . 4
[95% CI 0.5 to 4.3]). Individuals with both HLA-SE and any ACPA-positive had the highest risk of RA. HLA-SE-positive
RA cases showed reactivity to more ACPA types than HLA-SE negative (χ
2 test for trend, P =0 . 01 ).
Conclusions: There is increasing ACPA reactivity up to 10 years before RA onset with the strongest association
within 5 years of RA onset. The magnitude of the response to ACPAs, in combination with the presence of HLA-SE,
is most important for identifying those individuals with the highest risk of RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune inflamma-
tory arthropathy characterized by inflammation and auto-
antibodies directed against citrullinated peptides. The
anticyclic citrullinated peptide (anti-CCP) test, a commer-
cial assay that relies upon reactivity to several modified or
synthetic CCPs, is a useful assay for diagnosing RA and is
highly specific for RA [1]. Recently, research has focused
on autoantibodies directed against specific proteins and/or
peptides found in the synovium, such as vimentin, fibrino-
gen and enolase [2-7], in an effort to identify a specific
antigen responsible for inciting RA. Patients with RA may
be positive for more than one anticitrullinated peptide
antibody (ACPA), and there appears to be epitope spread-
ing of ACPA reactivity in the years leading up to diagnosis
[5,6,8-10].
Human leukocyte antigen (HLA)-DRB1 shared epitope
(HLA-SE) alleles are the strongest genetic risk factors for
RA, carrying a two- to threefold increased risk [11-13].
Past case–control studies have found that having both
HLA-SE and anti-CCP antibodies confers a greater risk of
developing RA than either one alone [14-16]. Among
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likely to have anti-CCP antibodies [2,4,17-21].
Most studies of individual ACPAs and RA risk have in-
cluded patients with early or well-established RA, and
those that have included pre-RA patients have not exam-
ined the combined effect of ACPA and HLA-SE.O u ro b -
jective in the present study was to characterize reactivity
to ACPAs targeted to epitopes found in the rheumatoid
synovium in the preclinical period before RA onset using
a nested case–control design within the Nurses’ Health
Study (NHS) and Nurses’ Health Study II (NHSII) cohorts.
We examined the relationship between the number of
ACPAs recognized and the time interval until RA symp-
tom onset. Furthermore, we aimed to understand the
interaction between ACPA and HLA-SE in determining
RA risk within this preclinical window.
Methods
Study design and population
The NHS is a prospective cohort of 121,700 female nurses
ages 30 to 55 years living in 11 states in 1976. The NHSII
is a similar cohort started in 1989 of 116,430 female
nurses ages 25 to 42 years living in 14 states in the United
States. The NHS and NHSII participants completed ques-
tionnaires at baseline and every 2 years afterward regard-
ing diseases, lifestyle and health practices. From 1989 to
1990, 32,826 NHS participants (27%) provided blood sam-
ples, and from 1996 and 1999, 29,611 NHSII participants
(25%) provided blood samples for future studies. We ex-
cluded women with any history of cancer (except nonme-
lanoma skin cancer) at the time of blood draw. All aspects
of this study were approved by the Partners’ HealthCare
System’s institutional review board. The participants’ re-
turn of a completed questionnaire was accepted as in-
formed consent and was approved by the review board.
Identification of rheumatoid arthritis cases
Methods of RA case identification and validation have
been described in detail in past publications [22,23].
Briefly, nurses who self-reported a doctor-diagnosed
connective tissue disease underwent a screening question-
naire for symptoms using the Connective Tissue Diseases
Screening Questionnaire [24]. If the result was positive, a
detailed medical record review was performed to deter-
mine definite RA using the American College of Rheuma-
tology (ACR) classification criteria [25]. Individuals who
met four of seven of the ACR criteria documented in the
medical record were defined as cases. There were a small
number of cases included as incident RA with only three
of the ACR criteria and a physician’s diagnosis, but further
agreed upon by two rheumatologists on the basis of chart
review (n=8). There were 11 cases with a missing date of
symptom onset; in those cases, we therefore imputed the
time of onset by assuming that the time between onset
and diagnosis was similar to those in the rest of the cases
(median time between onset and diagnosis was 6 months).
Only cases with a blood draw at least 3 months before
symptom onset were included.
Identification of matched controls
Three controls for each confirmed incident RA case
were randomly chosen from among participants with
stored blood, matched on age (±1 year), menopausal
status and postmenopausal hormone use, as well as on
time of data collection and fasting status at blood draw.
In NHSII, premenopausal women were also matched on
timing of blood sample in the menstrual cycle. We ex-
cluded from the control group any self-reported RA not
confirmed by a doctor and any participants who re-
ported other connective tissue diseases.
Laboratory methods
Anticitrullinated peptide antibodies
Potential RA-associated antigens identified from the litera-
ture and through proteomic screening [26] were coupled
to spectrally distinct beads using the BioPlex multiplex
assay platform (Bio-Rad Laboratories, Hercules, CA, USA)
for analysis and a Luminex 200 instrument (Luminex,
Austin,TX, USA) as previously described [6]. Three prees-
tablished control serum samples consisting of high re-
activity, low reactivity and no reactivity were run on each
plate as internal controls: negative, low positive and high
positive. Reactivities to 18 ACPAs targeted to synovial epi-
topes were measured in raw fluorescent intensity units
and determined to be positive if they were more than
three times the standard deviation above the mean in con-
trols. A less conservative cutoff of more than two times
the standard deviation was used in sensitivity analysis.
ACPA targets included citrullinated enolase, biglycan,
clusterin, fibrinogen, histone 2A, histone 2B and vimentin.
Three native peptides were also assayed to serve as con-
trols (fibrinogen, histone 2B and vimentin). A detailed list
of each ACPA target can be found in Additional file 1:
Table S1. Intrabatch coefficients of variation (CVs) were
4% to 10%, and interbatch CVs were 6% to 16%. We ex-
amined reactivity to any ACPA overall, ACPAs by peptide
group (for example, reactivity to any citrullinated clusterin
peptide) and individual ACPAs. A count of ACPAs was
carried out by adding the number of positive ACPAs. An
anti-CCP second-generation assay was performed by
bead-based microarray using beads coated with peptide
antigen (generously provided by Bio-Rad Laboratories). A
relative fluorescence value greater than 1,500 was consid-
ered anti-CCP-positive, as this cutoff was determined to
have similar sensitivity and specificity to a variety of plate-
based, anti-CCP2 enzyme-linked immunosorbent assays.
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HLA low to intermediate typing was performed by One
Lambda LABType reverse SSO Luminex DNA typing
method (One Lambda, Canoga Park, CA, USA). First,
target DNA was PCR-amplified using biotinylated group-
specific primers. The PCR product was then denatured
and hybridized to sequence-specific oligonucleotide
probes bound to fluorescently coded microspheres to
identify alleles encoded by the sample DNA. A flow
analyzer, the Luminex 200, identified fluorescence in-
tensity of R-phycoerythrin-conjugated streptavidin on
each microsphere. The assignment of the HLA typing
was based on the reaction pattern compared to probe
specificities associated with published HLA gene se-
quences. HLA high-resolution typing was performed by
sequencing. HLA locus-specific amplification was per-
formed in a thermal cycler using the amplification primer
mix and template DNA. Sequencing was performed
using BigDye Terminator sequencing chemistry (Applied
Biosystems, Foster City, CA, USA). Group-specific sequen-
cing primers were used when necessary to resolve allele-
specific ambiguities. We defined HLA-SE-positive as those
having at least one SE allele (HLA-DRB*0401, 0404, 0405,
0408, 0101, 0102, 1001 or 09). HLA-SE data were available
for 190 cases and 283 controls from another study. The
distribution of demographics and potential confounders in
this subset with HLA-SE data was similar to that of the full
study population.
Statistical analysis
Covariates were collected from the questionnaire before
blood draw and were selected for analysis if associated
with RA. Continuous variables included were pack-years
of smoking, measured by the product of years of smoking
and packs of cigarettes per day [27-29]; cumulative aver-
age alcohol intake in grams per day [28,30]; and body
mass index (BMI) in kilograms per square meter [31]. Less
than 1% of study participants had missing data for each
continuous covariate; therefore, median values from the
control group were imputed. Irregular menses [22] was in-
cluded as a dichotomous variable, and an indicator was
used for missing data.
Risk ratios (RRs) and their 95% confidence intervals
(95% CIs) were obtained from conditional logistic regres-
sion models. Multivariable models included age at blood
draw, pack-years of smoking, BMI, alcohol intake and ir-
regular menses. Multivariable Cox proportional hazards
models, including an interaction term for each ACPA and
time from blood draw to symptom onset, were used to
examine whether the association between each ACPA and
RA varied over time. Preclinical RA cases were stratified
into subgroups based on time between blood draw and
onset of RA. Because each participant donated a single
blood sample, the subgroups were mutually exclusive.
Effect modification of the association between ACPA posi-
tivity and RA by HLA-SE was assessed using uncondi-
tional logistic regression with adjustment for matching
factors. The ratio of odds ratios was calculated to examine
the multiplicative interaction between ACPA and HLA-SE,
and additive interaction was assessed by calculating the
synergy index (S) [32]. A χ
2 test for trend was used to
compare categorical ACPA count over time intervals. To
determine if HLA-SE was associated with peptide-specific
ACPAs, we used logistic regression models.
Results
We included 192 cases and 567 controls in the study (8
matched sets had fewer than 3 controls). On average,
compared to controls, cases were more likely to have ever
smoked cigarettes and drank less alcohol prior to blood
draw (Table 1). Cases had a mean age of 59.9 years at
Table 1 Characteristics of preclinical rheumatoid arthritis
cases and matched controls at time of blood collection in
the Nurses’ Health Study and Nurses’ Health Study II
a
Characteristics RA cases
(N=192)
Matched controls
(N=567)
Cohort, n (%)
NHS 136 (70.8) 405 (71.4)
NHSII 56 (29.2) 162 (28.6)
Caucasian, n (%) 190 (99.0) 556 (98.1)
Mean age at blood collection, years (SD) 52.3 (8.0) 52.4 (8.1)
Never smoker, n (%) 83 (43.2) 279 (49.2)
Current smoker, n (%) 33 (17.2) 82 (14.5)
Past smoker, n (%) 76 (39.6) 206 (36.3)
Mean pack-years of smoking
b (SD) 23.1 (16.4) 20.8 (18.8)
Mean alcohol intake, g/day (SD) 4.2 (5.6) 5.7 (8.9)
Mean BMI, kg/m
2 (SD) 26.1 (5.0) 25.0 (4.4)
Premenopausal, n (%) 65 (33.9) 193 (34.0)
Parous, n (%) 175 (91.1) 511 (90.1)
Irregular menses, n (%) 32 (16.7) 56 (9.9)
Positive for any ACPA, n (%) 48 (25.0) 38 (6.7)
Positive for anti-CCP, n (%) 23 (12.0) 0 (0)
Mean age at RA diagnosis, years (SD) 59.9 (9.9)
Mean time to RA onset, months (SD) 91.1 (53.6)
Median time to RA onset, months (IQR) 87.5 (92.0)
Morning stiffness, n (%) 143 (74.5)
Arthritis three or more joint areas, n (%) 176 (91.7)
Hand arthritis, n (%) 191 (99.5)
Symmetric arthritis, n (%) 188 (97.9)
Nodules, n (%) 21 (10.9)
Erosions, n (%) 43 (22.4)
aACPA: anticitrullinated peptide autoantibody, BMI: body mass index, CCP:
cyclic citrullinated peptide, NHS: Nurses’ Health Study, NHSII: Nurses’ Health
Study II, RA: rheumatoid arthritis.
bPack-years among ever smokers only.
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diagnosis was 7.3 years (range: 4 months to 17.3 years). At
the time of blood draw, 25.0% of cases and 6.7% of con-
trols were positive for at least one ACPA (Table 1).
The RR associated with any ACPA-positive was 4.9 (95%
CI=2.9 to 8.2; P<0.0001). Each ACPA within each pep-
tide type was significantly associated with risk of RA. RRs
ranged from 4.7 to 11.7 (Table 2). All individual ACPAs
were associated with RA, except for fibrinogen A 211–230
citrullinated cyclic (Additional file 1: Table S1).
Relationship of anticitrullinated peptide autoantibodies to
time to rheumatoid arthritis onset
The association between each ACPA and RA varied sig-
nificantly by time from blood draw to onset (P<0. 00 01
for interaction with time in Cox proportional hazards
model). Therefore, we examined the associations among
pre-RA subgroups stratified by time to onset within three
time windows (less than 5 years, 5 years to less than
10 years and 10 years or longer). The highest reactivity for
each ACPA was observed in the subgroup within the time
interval closest to onset (Figure 1). Any ACPA-positive
was associated with an almost 18-fold increased risk for
the subgroup within 5 years of onset (RR=17.6 (95% CI=
5.8 to 53.7)) and a 4-fold increased risk for the subgroup
with blood draws 5 to 10 years before onset (RR=4.2
(95% CI=1.7 to 10.4)). There was no statistically signifi-
cant increased risk in the subgroup with blood draws
10 years or more before RA onset (RR=1.4 (95% CI=0.5
to 4.3)) (Figure 1).
Among cases, the number of positive ACPAs was higher
the closer the blood draw was to onset. Cases with RA on-
set sooner after blood draw showed, on average, more re-
activity to more ACPAs (Figure 2). We observed a similar
trend in higher anti-CCP titers the closer to onset. The
number of specific positive ACPAs by time period in cases
and controls is listed in Additional file 2: Table S2. When
we examined fibrinogen alone, for which we tested seven
separate citrullinated peptide reactivities, we found that
the number of citrullinated fibrinogen antibodies was
higher in those cases with blood draw closer to onset
(Figure 3) (P =0.0 03byχ
2 test for trend).
When cases were restricted to those diagnosed within
5 years of blood draw, the sensitivity of an ACPA-positive
test was 42.2% and the specificity was 93.3%. In compari-
son, anti-CCP-positive sensitivity was 26.6% and the speci-
ficity was 100%. Characteristics of the RA cases diagnosed
within 5 years of blood draw are described in Additional
file 3: Table S3.
Relationship between anticitrullinated peptide
autoantibody and HLA-SE
The HLA-SE-positive/ACPA-positive group carried the
highest risk of RA. Comparing those who were HLA-
SE-positive and ACPA-positive to those who were nega-
tive for both, the overall OR was 10.4 (95% CI=4.3 to
25.2). When we compared just those with blood draws
less than 5 years before RA onset, the OR was 33.3 (95%
CI=11.1 to 99.6) (Table 3). There was a positive but not
statistically significant interaction for the additive scale,
suggesting the presence of excess risk from interaction
between ACPA and HLA-SE relative to the risk from
ACPA and HLA-SE without interaction (S=4.5 (95% CI
=0.9 to 24.5); P =0 .0 6) .RApatien tsw how ereHLA-SE-
positive showed reactivity to more ACPA types than
those who were HLA-SE-negative (P =0 .0 1byχ
2 test for
trend) (Figure 4). Only 1 of 23 HLA-SE-negative cases
had five or more positive ACPAs, whereas 15 of 40
HLA-SE-positive cases were positive for five or more
ACPAs. We further examined the association between
HLA-SE and each ACPA using logistic regression
models for cases only. We found that antibodies to
citrullinated clusterin and vimentin were associated
with HLA-SE in patients diagnosed within any time
period after blood draw. HLA-SE was associated with
citrullinated fibrinogen only within the time interval
closest to onset (P <0.05).
Table 2 Anticitrullinated peptide autoantibodies in women and risk of future rheumatoid arthritis in the Nurses’
Health Study and the Nurses’ Health Study II
a
ACPA target Positive cases (N= 192) Positive controls (N=567) Unadjusted RR (95% CI) P value Adjusted RR (95% CI) P value
Any ACPA 48 38 4.9 (3.0 to 7.8) <0.0001 4.9 (2.9 to 8.2) <0.0001
Biglycan 10 5 6.0 (2.1 to 17.5) 0.001 4.7 (1.6 to 14.2) 0.006
Clusterin 25 7 12.2 (5.0 to 29.8) <0.0001 11.7 (4.7 to 26.3) <0.0001
Enolase 5 3 5.0 (1.2 to 20.9) 0.03 5.8 (1.3 to 27.1) 0.02
Fibrinogen 37 22 6.3 (3.5 to 11.4) <0.0001 5.9 (3.2 to 11.0) <0.0001
Histone 2A 13 8 4.9 (2.0 to 11.8) <0.001 5.3 (2.1 to 13.2) <0.001
Histone 2B 18 8 7.3 (3.1 to 17.6) <0.0001 7.0 (2.8 to 17.2) <0.0001
Vimentin 28 11 9.8 (4.5 to 21.6) <0.0001 9.7 (4.3 to 21.8) <0.0001
aACPA: anticitrullinated peptide autoantibody, CI: confidence interval, RR, risk ratio. RR and 95% CI were estimated by using conditional logistic regression models
including matching factors and further adjusted for age at blood draw, alcohol intake, body mass index, regularity of menses and pack-years of smoking.
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In this large, prospective cohort study of women followed
for many years, we have demonstrated that the majority of
a panel of 18 different ACPAs targeted to epitopes in the
rheumatoid synovium are strongly associated with risk of
future RA. The highest reactivity for each of these ACPAs
was observed in the subgroup within 5 years of RA symp-
tom onset. Having any ACPA reactivity was associated
with an almost 18-fold increased risk of RA among
the subgroup within 5 years of RA symptom onset and a 4-
fold increased risk within the subgroup with blood draws 5
to 10 years before RA symptom onset. The higher number
of ACPAs and the higher overall ACPA reactivity closer to
t h et i m eo fR Ao n s e tm a yb ei n d i c a t i v eo fe p i t o p e
spreading, as has been reported in prior studies [5,6,9,10].
We also found that HLA-SE-positive RA cases showed re-
a c t i v i t yt om o r eA C P As u b t y p e st h a nHLA-SE-negative
cases and that antibodies to citrullinated clusterin and
vimentin were most strongly associated with HLA-SE-posi-
tive RA.
Three recent case–control studies have identified individ-
uals with stored blood who later developed RA. A blood
donor study in the Netherlands examined five ACPAs in
seventy-nine donors who gave blood multiple times before
they developed RA [5]. Another study analyzed 17 ACPAs
using a multiplex panel similar to the panels used in our
study in stored serum samples from the US Department of
Defense Serum Repository, including 81 individuals who
<5 years
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between blood draw and rheumatoid arthritis (RA) diagnosis date in cases and index date in controls in the Nurses’ Health Study (NHS) and the
Nurses’ Health Study II (NHSII). ELISA: enzyme-linked immunosorbent assay.
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study examined 10 ACPAs in 374 individuals who had do-
nated blood in Sweden before RA diagnosis [10]. (A subset
of these cases was reported by van der Woude et al.[ 9 ] ) .
These pre-RA studies also showed increased ACPA reactiv-
ity in time periods closest to disease diagnosis and an ex-
pansion of the ACPA repertoire over time among cases.
Our results are not directly comparable to those from the
Netherlands and Sweden, as we used a different panel of
ACPAs. However, we employed the same panel of ACPAs
tested in the prior US study [6] and found that all peptide-
specific ACPAs were associated with a fivefold or greater
increased risk of RA.
None of the blood bank studies cited above examined
the combined effect of ACPA positivity and HLA-SE on
RA risk, however, nor were the investigators able to ad-
just for potential confounders such as smoking. In the
current study, the presence of HLA-SE and any ACPA
together conferred an increased risk of RA: a 10-fold in-
creased risk overall and a 33-fold increased risk within
5 years of RA onset. This particular group of individuals
is at an especially high risk of imminent RA.
One previous case–control study of pre-RA cases
from a Swedish blood donor bank compared those
with HLA-SE alleles and commercial anti-CCP assay
positivity to those with neither and calculated an OR
for RA of 66.8 (95% CI =8.3 to 549.4) [15]. Re-
searchers in previous studies that included patients
with established RA or early RA symptoms have
found that the combination of a positive anti-CCP
test measured close to the time of diagnosis of RA
or individual ACPAs and HLA-SE was greater than
the effect of each alone [14,16,33]. However, these
findings address a different question: whether ACPAs
and HLA-SE are predictive of RA among patients
who already have symptoms.
Figure 3 Number of anticitrullinated fibrinogen antibodies in pre–rheumatoid arthritis cases by years prior to rheumatoid arthritis
diagnosis. Number of anticitrullinated fibrinogen antibodies in subgroups of cases diagnosed (a) 10 years or more (b) 5 years to less than
10 years and (c) less than 5 years before diagnosis of rheumatoid arthritis (RA) in the Nurses’ Health Study and Nurses’ Health Study II. ACPA:
anticitrullinated peptide antibody.
Table 3 Odds ratios for rheumatoid arthritis by anticitrullinated peptide autoantibody positivity and presence
of HLA-SE
a
ACPA-negative ACPA-positive
Parameter
Cases
(N=36)
Controls
(N=268) OR (95% CI)
Cases
(N=27)
Controls
(N=15) OR (95% CI)
OR (95% CI) for ACPA
within strata of HLA-SE
HLA-SE absent 17 153 1.0 (ref) 6 8 7.7 (2.2 to 27.5) 7.7 (2.2 to 27.5)
P=0.002 P= 0.002
HLA-SE present 19 115 1.4 (0.7 to 2.9) 21 7 33.3 (11.1 to 99.6) 23.8 (7.9 to 71.8)
P= 0.38 P<0.0001 P< 0.0001
OR (95% CI) for HLA-SE present 1.4 (0.7 to 2.9) 4.3 (1.0 to 18.6)
within strata of ACPA P= 0.38 P=0.05
aACPA: anticitrullinated antibody, CI: confidence interval, HLA-SE: human leukocyte antigen shared epitope, OR, odds ratio, ref: reference value. Measure of effect
modification on the additive scale: Synergy Index = 4.5 (95% CI = 0.9 to 21.6; P =0.06). Measure of effect modification on the multiplicative scale: ratio of odds ra-
tios = 3.1 (95% CI = 0.6 to 15.8; P= 0.18). ORs estimated by logistic regression models adjusted for matching factors and age at blood draw, alcohol intake, body
mass index, regularity of menses and pack-years of smoking. Restricted to cases with blood draw less than 5 years before diagnosis (cases = 63, controls= 283) in
the Nurses’ Health Study and Nurses’ Health Study II.
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those with HLA-SE had a more diverse ACPA repertoire.
Hill and colleagues have demonstrated that major histo-
compatibility complex class II molecules containing the
shared epitope had higher affinity for citrullinated pep-
tides in mice and that citrullinated peptide modification
activated a CD4+ T-cell response [34]. We observed that
HLA-SE was associated with anticitrullinated vimentin
and fibrinogen reactivity in particular, which is congru-
ent with reports by van der Woude et al. (vimentin) [9]
and van de Stadt et al. (fibrinogen) [8]. We have further
demonstrated that HLA-SE was associated with anti-
bodies to citrullinated clusterin. In this study, we have
included ACPAs directed toward well-established pep-
tide targets (fibrinogen, vimentin and enolase [35]) as
well as newer targets (biglycan, clusterin and histones
2A and 2B), all of which have been shown to be associ-
ated with RA. The association between 17 different
citrullinated peptides (7 different peptide types) and RA
risk suggests that the magnitude and diversity of recog-
nition to many different ACPAs is key to understanding
the immune response in the preclinical time period [36].
The generalizability of our study may be limited, as we
studied the NHS cohorts, which include only women, but
it is thought that RA pathogenesis is similar in men and
women. We had only one blood sample per individual;
therefore, it was not possible to investigate epitope spread-
ing over time in a single individual. With a follow-up after
blood draw of up to 17 years (longer follow-up than previ-
ous studies of pre-RA), we were able to investigate if there
was an early rise in ACPAs more than 10 years prior to
RA onset. Our study helps to increase understanding of
the diversity of ACPAs before onset using a relatively large
sample of pre-RA cases. We included a large, up-to-date
ACPA panel, which enabled us to study ACPA count in
relation to HLA-SE and RA onset date, which may be
more relevant than one ACPA alone in the years leading
up to disease onset. This study is also strengthened by the
use of data on health and lifestyle factors taken from ques-
tionnaires before blood draw, which allowed us to adjust
for potential confounders.
Conclusions
We found that a diverse ACPA repertoire is associated
with HLA-SE and is strongest within 5 years of onset of
RA. Our study suggests that there is a broader citrulli-
nated epitope recognition profile instead of one ACPA be-
ing responsible for inciting disease. The magnitude of the
response to ACPAs in combination with the presence of
HLA-SE may be most important for determining the risk
of disease. In the future, researchers should continue to in-
vestigate whether individual environmental factors trigger
the development of ACPA reactivity and immune dysregu-
lation in the peripheral blood before RA onset.
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